{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-002928","form_type":"8-K","ticker":"OGEN","cik":"0001174940","company_name":"ORAGENICS INC","filed_at":"2025-01-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.087364+00:00","generated_at":"2026-05-27T21:56:39.699875+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Oragenics appoints CFO Janet Huffman as interim CEO; provides ONP-002 Phase II timeline","bullets":["CFO Janet Huffman named interim CEO, retaining CFO role; board expresses confidence in her leadership.","Company raised $4M in September 2024; progress includes improved ONP-002 formulation and device prototyping.","Phase II trial in Australia: first patient dosing targeted by end of Q1 2025 or early Q2 2025.","IND package for U.S. Phase IIb clinical trial targeted for Q3 2025.","Spray-dry campaign completed to ensure sufficient drug-device units for upcoming trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-002928","json":"https://secwatch.observer/filing/0001493152-25-002928.json","markdown":"https://secwatch.observer/filing/0001493152-25-002928.md","text":"https://secwatch.observer/filing/0001493152-25-002928.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1174940/000149315225002928/0001493152-25-002928-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1174940/000149315225002928/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T21:56:39.699875+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}